Research on MDMA and schizophrenia reopens an uncomfortable but necessary debate on safety, ethics, and the cost of not studying what has long been forbidden.
There are debates that drag on not because of a lack of data, but because of an excess of fear. The debate surrounding psychedelics and psychosis is one of them. A circular discussion, almost a dog chasing its own tail: because there is a theoretical risk of psychotic decompensation, people with schizophrenia or other psychotic spectrum disorders are systematically excluded from clinical trials; and by excluding them, we never manage to determine with scientific rigor whether that risk is real, under what conditions it emerges, or how it might be minimized.
The result is a form of institutionalized ignorance masquerading as prudence, as José Carlos Bouso, scientific director of Fuertedélica, has pointed out.
Against this backdrop, the fact that two world-renowned schizophrenia researchers, John Kane and Stephen Marder, are collaborating on studies examining the tolerability and efficacy of MDMA in this patient population is far from anecdotal. It is a political gesture in the best sense of the word: a decision to look directly at what for decades has been deliberately avoided.
Beyond Positive Symptoms
The focus of these studies is not on the so-called positive symptoms—delusions and hallucinations—that dominate public narratives about schizophrenia, but on the negative symptoms: poverty of thought, reduced speech, social withdrawal, lack of motivation. These symptoms are the most persistent, the most disabling, and paradoxically the least effectively treated.
For many people living with schizophrenia, it is not psychosis itself that hurts the most, but the inner silence—the feeling of a blocked mind that prevents them from engaging with the world in a flexible, meaningful way.
Early Observations and Neurobiological Clues
This line of inquiry does not emerge from nowhere. As early as the beginning of the 2000s, several case reports described individuals with schizophrenia who experienced a temporary relief from their symptoms after using MDMA recreationally. They reported a sense of mental quiet, a loosening of rigid cognitive patterns, and an unexpected capacity for emotional and social connection. These observations were fragile, anecdotal, and far from definitive—but they were also too consistent to be dismissed outright.
Neurobiology offers pieces that appear to fit together. We know that MDMA acts on serotonin and dopamine systems and has adrenergic effects as well. We know it enhances prepulse inhibition, a neurophysiological marker that is typically diminished in schizophrenia. We also know that MDMA dampens amygdala activity, facilitates fear extinction, reduces sensitivity to social threat, and increases oxytocin availability.
Trust and bonding are primed, alongside a state of heightened neuroplasticity that, in some respects, resembles adolescent sensitivity to social cues. This does not make MDMA a miracle cure. But it does suggest it could become a therapeutic tool—particularly for strengthening the therapeutic alliance.
A Cautious Clinical Approach
Trusting, engaging, and revisiting rigid cognitive structures are not secondary concerns in psychiatry; in many cases, they are the very foundation of meaningful treatment. It is in this context that a small pilot study involving twelve participants is being proposed at Zucker Hillside Hospital, affiliated with Northwell Health, the largest healthcare provider in New York State.
The design is deliberately cautious: strict inclusion criteria, unmedicated participants, a predominance of negative symptoms, and strong family support to reduce the risk of behavioral destabilization. This is not about minimizing risk by denying it exists, but about managing it through careful methodology and close supervision.
European Warnings and the Question of Safety
At the same time, voices from Europe urge caution. A recent correspondence in Molecular Psychiatry by Albert Batalla and colleagues underscores how elusive the concept of “safety” remains when discussing psychedelics and psychosis. The available evidence is scarce, outdated, and heterogeneous. Much of what we believe we know rests on just two studies conducted in the 1950s and 1960s.
Rather than demonstrating a clear additional risk, the data suggest that any increased vulnerability may be modest and highly dependent on context, dosage, and patient selection. Yet the authors’ warning extends beyond the laboratory. There is legitimate concern that irresponsible communication—amplified by non-scientific media or commercial interests—could distort public risk perception and fuel non-medical use, with unpredictable public-health consequences.
Learning from Cannabis Without Repeating Its Mistakes
The history of cannabis legalization serves as a cautionary tale: early medical acceptance, followed in some jurisdictions by rapid normalization and insufficient preventive frameworks. But caution must not harden into paralysis. The cannabis precedent teaches us not that research should be avoided, but that it should be conducted earlier, more rigorously, and with clearer regulatory and communicative boundaries.
Importantly, the data also show meaningful differences: transition rates from substance-induced psychosis to schizophrenia are substantially higher for cannabis than for serotonergic psychedelics.
The Ethical Cost of Not Knowing
This raises a deeper ethical question, one that is rarely articulated: what is the human cost of not researching? How many people remain trapped in profoundly disabling negative symptoms because we have collectively decided—without robust evidence—that it is safer not to try?
Prudence that is never revisited risks becoming a form of neglect. An increasing number of researchers are now arguing for the progressive and carefully controlled inclusion of individuals with psychotic disorders in clinical trials. Among them is psychiatrist Julie Holland, who has publicly proposed studying MDMA in people with psychosis—not from naïve enthusiasm, but from clinical responsibility.
Letting Science Do Its Work
Legalization and regulation do not mean trivialization. On the contrary, they create the conditions for better science, better training, clearer communication, and stronger protections for vulnerable populations. The goal is not to romanticize psychedelics, but to stop fearing them uncritically.
Science moves forward by asking uncomfortable questions. And few questions today are more uncomfortable—or more necessary—than this one.
Raúl del Pino is a prominent psychonaut, writer, and authority on psychoactive substances, particularly psychedelics.
He founded www.psiconautica.org in 1996, the first Spanish-language website dedicated to drugs, focusing on Altered States of Consciousness and Transpersonal Psychology. He is the author of the books Contemporary Guide to the Psychedelic Journey and MDMA, Sex, and Tantra. Raúl combines scientific rigor with personal introspection, exploring the relationship between psychoactives, sexuality, and spiritual practices. His work makes a significant contribution to the understanding and responsible use of psychoactive substances.